KLF8: A Potential Drug Target and Biomarker (G11279)

Target Name: KLF8

NCBI ID: G11279

KLF8

KLF8: A Potential Drug Target and Biomarker

Kruskal-Wallis (KW) is a mathematical technique used to analyze the distribution of data in a set. It is a widely used method for identifying patterns in data and is commonly used in scientific research. In recent years, KW has been used as a tool to identify potential drug targets and biomarkers. One such example is KLF8, which is a Basic Kruppel-like factor 3 (BKLF3) gene that has been identified as a potential drug target and biomarker.

The KLF8 gene is a member of the BKLF3 gene family, which is known for its role in various cellular processes. BKLF3 genes are involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. The regulation of cell adhesion is a critical process that is involved in many diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the unique features of KLF8 is its ability to interact with several different proteins, including the protein known as Focal Adhesion kinase (FAK). FAK is a protein that is involved in many different cellular processes, including cell adhesion, migration, and invasion. It is also a known driver of many diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The interaction between KLF8 and FAK suggests that KLF8 may be a useful drug target for the treatment of these diseases. By inhibiting the activity of FAK, it may be possible to reduce the growth and spread of cancer cells, improve the progression of neurodegenerative diseases, and treat developmental disorders.

In addition to its potential as a drug target, KLF8 has also been identified as a potential biomarker for several diseases. The regulation of cell adhesion is a critical process that is involved in many diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, it is possible that changes in the regulation of cell adhesion, as occurred in KLF8, may be a useful indicator of the presence or progression of these diseases.

KLF8 has also been shown to be involved in the regulation of several other cellular processes, including cell cycle progression, angiogenesis, and inflammation. Therefore, it is possible that KLF8 may be a useful biomarker for the diagnosis and treatment of diseases that are characterized by these processes.

In conclusion, KLF8 is a gene that has been identified as a potential drug target and biomarker. Its interaction with the protein FAK and its involvement in the regulation of cell adhesion suggest that it may be a useful target for the treatment of diseases that are characterized by the regulation of cell adhesion. Further research is needed to confirm these findings and to develop safe and effective treatments for KLF8-related diseases.

Protein Name: KLF Transcription Factor 8

Functions: Transcriptional repressor and activator. Binds to CACCC-boxes promoter elements. Also binds the GT-box of cyclin D1 promoter and mediates cell cycle progression at G(1) phase as a downstream target of focal adhesion kinase (FAK)

The "KLF8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLF8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets